Clinical trial · Observational
Occurrence of Acute Kidney Injury After CAR-T Cells Treatments in B-cell Lymphoma.
Incidence and Risk Factors of Acute Kidney Injury (AKI) After Anti-CD19 CAR-T Cells Treatments in B-cell Lymphoma and Long Term Evolution.
NCT07101913CI-TRIAL-00093047AKI CARactive not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators want to describe the incidence of AKI after CAR-T cells therapy in B-cell lymphoma. With the aim of highlight risk factors in AKI occurrence. Then, look at outcomes in the subgroup with chronic kidney disease at baseline. Finally, the investigators will examine long term evolution of kidney function.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Kidney Injury (AKI) | — | UNRESOLVED | — |
| B Cell Lymphoma | B-Cell Malignant Neoplasm | CURATED_BROADER | 0.80 |
| Infusion of CD19 CAR T Cell | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Describe risk factors in AKI occurrence. | Other | — | UNRESOLVED |
| Focus on patient with chronic kidney disease at baseline | Other | — | UNRESOLVED |
| Incidence of acute kidney injury | Biological | — | UNRESOLVED |
| Long term evolution after treatment by CAR-T cells | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- CAR-T cells treatment
- description
- All patients followed in haematology center in "Hospices civils de Lyon" for a B-cell lymphoma and treated by anti-CD19 CAR-T cells.
- interventionNames
- Biological: Incidence of acute kidney injury
- Other: Describe risk factors in AKI occurrence.
- Other: Focus on patient with chronic kidney disease at baseline
- Other: Long term evolution after treatment by CAR-T cells
Primary outcomes (1)
- measure
- Incidence of AKI after CAR-T cell therapy in B-cell lymphoma. In percentage, according to the 2012 KDIGO.
- timeFrame
- AKI from the day of the injection of CAR-T cells, until 28 days after the injection.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients followed in haematology center in "Hospices civils de Lyon" * For a B-cell lymphoma * Treated by anti-CD19 CAR-T cells Exclusion Criteria: * Less than 18 years old * Patients with legal protection measure * CAR-T cells therapy for another disease : leukemia, autoimmune disease…
References
Publications (0)
Data not yet available
No reference posted for this study.